Video
COVID-19 Pandemic Provides Opportunities to Innovate With Oral Oncolytics, Medically Integrated Dispensing
Shereen Stutz and Mark Alwardt, of McKesson, said the rise in oral oncolytics during the COVID-19 pandemic allowed pharmacists to be more innovative and to become an even more integrated part of the oncology care team.
In an interview with Pharmacy Times, Shereen Stutz and Mark Alwardt, of McKesson, said the rise in oral oncolytics during the COVID-19 pandemic allowed pharmacists to be more innovative and to become an even more integrated part of the oncology care team.
In the interview, Stutz and Alwardt discussed the necessity for close monitoring when patients receive oral oncolytics, potential concerns about adherence, and how telemedicine enabled this care and monitoring. Stutz and Alwardt also co-authored an article on the subject, which will be featured in the October issue of Directions in Oncology Pharmacy.
